Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis

Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial

The aim of this study is to compare the efficacy of intralesional bevacizumab, a monoclonal antibody against vascular endothelial growth factor, versus the antiviral drug cidofovir in patients with recurrent respiratory papillomatosis.

The investigators designed a randomized, double-blind, placebo-controlled study. Children and adults will be randomized to receive either 3 dosis of intralesional bevacizumab, cidofovir or saline solution. Primary endpoints are the assessment of changes in the annual surgery rate and Derkay papilloma severity grading scale; secondary endpoints are changes in the Voice Handicap Index and safety.

Inclusion Criteria:

• Patients diagnosed with recurrent respiratory papillomatosis proven by biopsy.
• Patients with 2 or more previous surgeries for papillomatosis

Exclusion Criteria:

• Patients with heart or renal disease
• Patients who receive another adjuvant therapy